April 1985

Arterial Infusion of Dacarbazine and Cisplatin for Recurrent Regionally Confined Melanoma

Author Affiliations

From the Departments of Surgery (Dr Frost), Clinical Immunology and Biological Therapy (Drs Patt and Mavligit), and Diagnostic Radiology (Drs Chuang and Wallace), The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston. Dr Frost is a fellow of the American Cancer Society.

Arch Surg. 1985;120(4):478-480. doi:10.1001/archsurg.1985.01390280068015

• We treated nine patients who had metastatic malignant melanoma confined to one extremity (8/9) or the vulva (1/9) with arterial dacarbazine and cisplatin at respective doses of 800 and 90 mg/sq m. We percutaneously introduced catheters into the extremity or regional artery under fluoroscopy by the Seldinger technique, removed them at the end of the infusions, and repositioned them at four-week intervals for repeated treatment cycles. One patient achieved a complete remission, three patients had partial remissions, and five patients' disease was stable. The group median survival will exceed 19 months. Three patients with stable disease died 6,18, and 19 months after treatment initiation, respectively. The toxic effects were primarily nausea and vomiting, pain in the infused extremity, and local erythema. Arterial dacarbazine and cisplatin offer a more effective and less toxic alternative to higher-dose single-agent arterial cisplatin for locally advanced malignant melanoma.

(Arch Surg 1985;120:478-480)